- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Zydus Lifesciences Limited — Updates, 15-12-2025: Press Release
15-12-2025 | 06:30 pm
15-12-2025 | 06:30 pm
Zydus Lifesciences' subsidiary, Sentynl, secured FDA acceptance for its Menkes disease treatment, CUTX-101, NDA resubmission. A PDUFA target date of January 14, 2026, is set. This marks a significant step towards potentially launching the first approved therapy for the rare genetic condition.
No comments yet. Be the first to comment!